Mayo Clinic desarrolla herramienta que predice riesgo de Alzheimer años antes de los primeros síntomas Mayo Clinic researchers have developed a predictive tool utilizing data from the Mayo Clinic Study of Aging to estimate an individual’s risk of developing memory and thinking problems associated with Alzheimer’s disease years before symptoms manifest. The model incorporates age, sex, genetic risk (APOE genotype), and amyloid levels detected by PET scans, providing a probability of developing mild cognitive impairment or dementia. This advancement aims to enable earlier interventions and personalized care strategies to potentially delay symptom onset.

• Mayo Clinic researchers developed a tool to predict Alzheimer’s-related memory and thinking problems years before symptoms.
• The tool uses data from the Mayo Clinic Study of Aging, analyzing age, sex, genetic risk (APOE genotype), and amyloid levels.
• Women have a higher lifetime risk of dementia and mild cognitive impairment than men.
• Individuals with the APOE ε4 genetic variant have an increased lifetime risk of developing Alzheimer’s.
• Brain amyloid levels were the strongest predictor of lifetime risk.
• The prediction tool can estimate the likelihood of developing mild cognitive impairment or dementia within 10 years or a lifetime.
• This risk estimation could help individuals and doctors decide on treatment timing and lifestyle changes.
• The study highlighted the importance of complete, longitudinal data for accurate Alzheimer’s progression tracking.
• Future versions of the tool may include blood biomarkers for more accessible early detection.
• The ultimate goal is to provide individuals with more time to plan and act before memory problems become established. https://nicaragua-hub.syndichain.com/articles/fbed5dac-5827-4b88-b940-ba14feaa1757 https://www.portafolio.co/tendencias/sociales/mayo-clinic-desarrolla-herramienta-que-predice-riesgo-de-alzheimer-anos-antes-de-los-primeros-sintomas-484335